Editing the Genome to Cure Genetic Disease

Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.

Social Media

Local biotechs UniQure, Casebia step up race for new hemophilia drugs https://t.co/Gao2CSVaQ8

Senior Scientist Keith Abe from our #MissionBay office will be speaking next week at the @ACDbio Symposium in #SanFrancisco on the topic of ‘in vivo delivery of #Cas9 mRNA utilizing lipid nanoparticles in the mouse’ – learn more at: https://t.co/YLMBTgnR5l

See us on Twitter